NRIX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 13, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Apr 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Jan 28, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Oct 9, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 9, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Nurix Therapeutics Announces Discontinuation of SAR448272 Program by Sanofi

Nov 3, 2026

8-K

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates

Oct 13, 2026

8-K

Nurix Therapeutics Enters Global Collaboration with Roche for Bexobrutideg and Reports Q2 2026 Financial Results

Jul 9, 2026

8-K

Nurix Therapeutics Reports Updated Phase 1a/b Results for BTK Degrader Bexobrutideg

Jun 11, 2026

8-K

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Bexobrutideg

Jun 8, 2026

8-K

Nurix Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 15, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

March 2026 ATM | Offering amount: $413,650,000 | Bank: Piper Sandler & Co.

Mar 6, 2026

424B5

REGISTERED OFFERING

Oct 22, 2025

424B5

ATM | Offering amount: $300,000,000

Oct 31, 2024

424B5

Up to $150,000,000 Common Stock PROSPECTUS SUPPLEMENT Piper Sandler July 11, 2024

Jul 11, 2024

424B5

SHELF OFFERING | Shares amount: 10,166,667 | Share price: $15.00 | Warrants amount: 1,500,100 | Offering amount: $175,000,004.90

Apr 12, 2024

424B5

SHELF OFFERING | Share price: $15.69 | Offering amount: $125,000,000.00

Apr 11, 2024

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 28, 2026

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Oct 22, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Jan 28, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Oct 31, 2024

S-3ASR

Common Stock, Preferred Stock,

Jun 11, 2024

S-8

Registration

Feb 15, 2024

Proxies

TYPE

HEADLINE

FILED AT

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 5, 2026

van Houte Hans (Reporting)

Nov 4, 2026

Ring Christine (Reporting)

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Nov 3, 2026

van Houte Hans (Reporting)

Nov 2, 2026

Other

TYPE

HEADLINE

FILED AT

LETTER

Form UPLOAD - SEC-generated letter

Mar 19, 2025

CORRESP

Form CORRESP - Correspondence

Mar 13, 2025

LETTER

Form UPLOAD - SEC-generated letter

Feb 28, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 7, 2023

EFFECT

Form EFFECT - Notice of Effectiveness

Mar 5, 2021

CORRESP

Form CORRESP - Correspondence

Mar 2, 2021

Nurix Therapeutics, Inc. NRIX · SEC Filings